Patents Assigned to Clinical Technologies, Inc.
-
Publication number: 20070169774Abstract: An aerosol medication delivery apparatus includes a fixed volume holding chamber which is constructed to allow for a uniformly mixed, concentrated bolus of medicated aerosol to be delivered with each breath. The device further includes a universal inlet, so that any standard small volume nebulizer, as well as any standard metered dose inhaler (MDI), may be utilized therewith. Also filtration can be added to address contaminated patient air and aerosol. A one-way valve is positioned in the patient mouthpiece, to help control the loss of aerosol, and thereby reduce waste.Type: ApplicationFiled: March 23, 2007Publication date: July 26, 2007Applicant: Clinical Technologies, Inc.Inventors: Robert Johnson, Robert DuBose
-
Publication number: 20020121275Abstract: An aerosol medication delivery apparatus includes a fixed volume holding chamber which is constructed to allow for a uniformly mixed, concentrated bolus of medicated aerosol to be delivered with each breath. The device further includes a universal inlet, so that any standard small volume nebulizer, as well as any standard metered dose inhaler (MDI), may be utilized therewith. Also filtration can be added to address contaminated patient air and aerosol. A one-way valve is positioned in the patient mouthpiece, to help control the loss of aerosol, and thereby reduce waste.Type: ApplicationFiled: May 15, 2001Publication date: September 5, 2002Applicant: CLINICAL TECHNOLOGIES, INC.Inventors: Robert Johnson, Robert DuBose
-
Patent number: 6363932Abstract: An aerosol medication delivery apparatus includes a fixed volume holding chamber which is constructed to allow for a uniformly mixed, concentrated bolus of medicated aerosol to be delivered with each breath. The device further includes a universal inlet, so that any standard small volume nebulizer, as well as any standard metered dose inhaler (MDI), may be utilized therewith. Also filtration can be added to address contaminated patient air and aerosol. A one-way valve is positioned between the holding chamber and a tee piece for attaching the holding chamber to a patient mouthpiece, to help control the loss of aerosol, and thereby reduce waste. The device is simply constructed of two molded plastic members, which are readily engaged to complete its assembly.Type: GrantFiled: July 6, 2000Date of Patent: April 2, 2002Assignee: Clinical Technologies, Inc.Inventors: Dennis Forchione, Robert Johnson
-
Patent number: 6063374Abstract: A recombinant human immunodeficiency virus (rHIV) and recombinant mammalian cell-line (packaging systems) and a method for treating infection of cells by human immuneodeficiency virus HIV. rHIV, such as rHIV-1, comprises of a gene construction which includes a foreign gene. The expression of this gene is activated in human cells in the presence of wild-type HIV. This gene product can cause cell death in the presence of an appropriate drug, e.g. Acyclovir. This gene product is typically a viral thymidine kinase. rHIV is so constructed that it is unable to replicate by itself due to the absence of a regulatory gene that is necessary for its replication, such as tat or rev or both. The recombinant mammalian cell-line packaging system comprises in its genome a recombinant gene construction which typically includes a functional regulatory gene from HIV which is missing from rHIV, such as the tat or rev genes or both.Type: GrantFiled: November 28, 1995Date of Patent: May 16, 2000Assignee: Clinical Technologies, Inc.Inventors: Syed Zaki Salahuddin, Nickolas Chelyapov
-
Patent number: 5753490Abstract: A recombinant human immunodeficiency virus (rHIV) and recombinant mammalian cell-line (packaging systems) and a method for treating infection of cells by human immuneodeficiency virus HIV. rHIV, such as rHIV-1, comprises of a gene construction which includes a foreign gene. The expression of this gene is activated in human cells in the presence of wild-type HIV. This gene product can cause cell death in the presence of an appropriate drug, e.g. Acyclovir. This gene product is typically a viral thymidine kinase. rHIV is so constructed that it is unable to replicate by itself due to the absence of a regulatory gene that is necessary for its replication, such as tat or rev or both. The recombinant mammalian cell-line packaging system comprises in its genome a recombinant gene construction which typically includes a functional regulatory gene from HIV which is missing from rHIV, such as the tat or rev genes or both.Type: GrantFiled: November 28, 1995Date of Patent: May 19, 1998Assignee: Clinical Technologies, Inc.Inventors: Syed Zaki Salahuddin, Nickolas Chelyapov